Is it the Right Time to Hold STERIS Stock in Your Portfolio?

STERIS plc (STE), a provider of infection prevention products, is experiencing growth in its Healthcare and Applied Sterilization Technologies (AST) segments, driven by strong U.S. procedure volumes, favorable pricing, and service revenue, with Healthcare reporting 5% year-over-year revenue growth and AST seeing 9% growth. However, macroeconomic headwinds and adverse currency impacts pose concerns, with the company noting an 8% year-over-year increase in SG&A expenses and potential impacts on procurement costs and investment portfolio performance; despite these challenges, the Zacks Consensus Estimate for STERIS’ fiscal 2026 earnings has moved north 0.5% to $9.98.

Analysis

STERIS plc (STE) presents a mixed operational profile, with its Healthcare and Applied Sterilization Technologies (AST) segments delivering notable growth while the company navigates macroeconomic challenges and adverse currency impacts. Over the past year, STE's stock has appreciated 7.7%, outperforming the industry's 13.4% decline but trailing the S&P 500's 12.1% rise. The company, with a market capitalization of $24.61 billion, offers an earnings yield of 4%, significantly better than the industry's -2.5%, and has achieved an average earnings surprise of 2.05% in the trailing four quarters. Specifically, the Healthcare segment saw a 5% year-over-year revenue increase in the fiscal fourth quarter, driven by a 6% improvement in consumable revenues and 13% growth in service revenues, contributing to a 6% constant currency organic revenue growth and robust order growth exceeding 12%. The AST segment also demonstrated strength with a 9% year-over-year revenue growth in the same period, fueled by a 6% rise in service revenues and high single-digit constant currency organic revenue growth, alongside early signs of increased bioprocessing demand. However, with approximately 30% of revenues and costs generated internationally, foreign currency fluctuations pose a risk, as evidenced by an unfavorable impact in the fiscal third quarter. Macroeconomic pressures have also led to increased raw material costs and an 8% year-over-year escalation in selling, general, and administrative (SG&A) expenses in the fiscal fourth quarter. Despite these headwinds, the Zacks Consensus Estimate for STERIS’ fiscal 2026 earnings has edged up 0.5% to $9.98 in the past 30 days, with projected revenues of $5.81 billion indicating a 6.3% increase from fiscal 2025.

Key Decisions for Investors

• Investors should carefully weigh STERIS's demonstrated growth in its Healthcare and AST segments, alongside its positive earnings yield, against the persistent headwinds from foreign currency volatility and macroeconomic cost pressures, including rising SG&A expenses.
• Monitor upcoming financial reports for sustained margin performance, particularly in the Healthcare segment, and further signs of demand recovery in bioprocessing within the AST division, as these will be key indicators of the company's ability to navigate the challenging environment.
• While STERIS has outperformed its industry, its performance lags the broader market; consider the current Zacks Rank #3 (Hold) and the modest upward revision in fiscal 2026 earnings estimates when evaluating the risk-reward profile for existing or new positions.